New Triple-Drug attack shows promise for tough breast cancer

NCT ID NCT05286437

Ongoing Disease control Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This phase II study is testing a combination of three drugs—lenvatinib, pembrolizumab, and letrozole—in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy. The goal is to see if this combination can shrink tumors or slow disease progression. The study plans to enroll 40 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lenvatinib, Pembrolizumab, and Letrozole
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced breast cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a small, early-phase (phase II) study with only 40 participants. The combination may not work better than existing treatments, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

Contacts and locations

Locations

National Cancer Centre Singapore

Singapore, 169610, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.